Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>=18 years of age
Metastatic colorectal cancer and disease progression
Previously treated with first-line chemotherapy plus Avastin
Eastern Cooperative Oncology Group (ECOG) performance status \<=2.
You may not be if
Diagnosis of progression of disease more than 3 months after last Avastin administration
First-line patients with progression-free survival in first-line of \<3 months
Patients receiving less than 3 consecutive months of Avastin in first-line therapy
Past or current history (within the last 2 years prior to treatment start) of other malignancies, except for curatively treated basal and squamous cell cancer of the skin or in situ cancer of the cervix
Clinically significant cardiovascular disease within 6 months prior to start of study treatment
Known central nervous system (CNS) disease, except for treated CNS metastases as defined by protocol
Clareo Health | A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
